GPC3-IL7-CCL19-CAR-T主要用于肝细胞癌治疗的免疫微环境复制

Li-Li Lu1,2, Shu-Xiu Xiao1,2, Zhi-Yuan Lin3

  • 1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, China.

PubMed
概括

新型GPC3-7-19-CAR-T细胞通过增强T细胞功能和逆转瘤微环境,提高了治疗肝细胞癌 (HCC) 的疗效. 这种先进的仿真抗原受体 (CAR) -T细胞疗法在临床试验中显示出有前途的安全性和抗瘤作用.